- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00915863
Evaluation of Isolated Roux-en-Y Reconstruction After Pancreaticoduodenectomy
A Prospective Randomized Controlled Trial Comparing Isolated Roux-en-Y Reconstruction With Billroth-II-type Reconstruction After Pancreaticoduodenectomy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to clarify whether isolated Roux-en-Y reconstruction declines the incidence of postoperative complications after pancreaticoduodenectomy compared with Billroth-II-type reconstruction. Especially, it is important to decline the incidence of pancreatic fistula, because pancreatic fistula affects a postoperative course. However, there is no report that demonstrated postoperative complications of isolated Roux-en-Y compared with those of Billroth-II-type reconstruction. We conducted a prospective randomized trial on patients who underwent pancreaticoduodenectomy.
Patients with pancreatico-biliary disease who were performed pancreaticoduodenectomy at Wakayama Medical University Hospital.
The primary endpoint was defined as the incidence of pancreatic fistula. The secondary endpoints were the incidence of other postoperative complications, mortality, delayed gastric emptying, intra-abdominal hemorrhage, and intra-abdominal abscess. Patients were recruited into this study before surgery, on the basis of whether pancreatic head resection was anticipated at Wakayama Medical University Hospital (WMUH) for pancreatic head and periampullary disease, and appropriate informed consent was obtained. Exclusion criteria was 1) young patients (less than 20-year-old), 2) patients with severe complications which were possible to prolong hospital stay, 3) patients undergone hemodialysis, 4) patients combined resection of other organs, 5) patients who were diagnosed inadequacy for this study by a physician, and 6) patients without an informed consent.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Wakayama
-
811-1 Kimiidera, Wakayama, Wakayama, Japan, 641-8510
- Recruiting
- Wakayama Medical University , Second Department of Surgery
-
Contact:
- Hiroki Yamaue, MD
- Phone Number: +81-73-441-0612
- Email: yamaue-h@wakayama-med.ac.jp
-
Contact:
- Masaji Tani, MD
- Phone Number: +81-73-441-0613
- Email: matani@wakayama-med.ac.jp
-
Principal Investigator:
- Masaji Tani, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- the patients had undergone pancreatic head resection at Wakayama Medical University the patients obtained appropriate informed consent
Exclusion Criteria:
- young patients (less than 20-years-old)
- patients with severe complications which were possible to prolong hospital stay
- patients undergone hemodialysis
- patients combined resection of other organs
- patients who were diagnosed inadequacy for this study by a physician
- patients without an informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Billroth-II-type
Billroth-II-type reconstruction after pancreaticoduodenectomy
|
surgical procedure
Other Names:
|
|
Experimental: Isolated Roux-en-Y
Isolated Roux-en-Y type reconstruction after pancreaticoduodenectomy
|
surgical procedure
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
the incidence of pancreatic fistula
Time Frame: 3 months after operation
|
3 months after operation
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
the incidence of other postoperative complications, mortality, delayed gastric emptying, intra-abdominal hemorrhage, and intra-abdominal abscess
Time Frame: 3 months after operation
|
3 months after operation
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Masaji Tani, MD, Wakayama Medical University
Publications and helpful links
General Publications
- Kawai M, Tani M, Terasawa H, Ina S, Hirono S, Nishioka R, Miyazawa M, Uchiyama K, Yamaue H. Early removal of prophylactic drains reduces the risk of intra-abdominal infections in patients with pancreatic head resection: prospective study for 104 consecutive patients. Ann Surg. 2006 Jul;244(1):1-7. doi: 10.1097/01.sla.0000218077.14035.a6.
- Tani M, Kawai M, Terasawa H, Ina S, Hirono S, Uchiyama K, Yamaue H. Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer? J Surg Oncol. 2006 May 1;93(6):485-90. doi: 10.1002/jso.20440.
- Tani M, Terasawa H, Kawai M, Ina S, Hirono S, Uchiyama K, Yamaue H. Improvement of delayed gastric emptying in pylorus-preserving pancreaticoduodenectomy: results of a prospective, randomized, controlled trial. Ann Surg. 2006 Mar;243(3):316-20. doi: 10.1097/01.sla.0000201479.84934.ca.
- Tani M, Onishi H, Kinoshita H, Kawai M, Ueno M, Hama T, Uchiyama K, Yamaue H. The evaluation of duct-to-mucosal pancreaticojejunostomy in pancreaticoduodenectomy. World J Surg. 2005 Jan;29(1):76-9. doi: 10.1007/s00268-004-7507-0.
- Tani M, Kawai M, Terasawa H, Ueno M, Hama T, Hirono S, Ina S, Uchiyama K, Yamaue H. Complications with reconstruction procedures in pylorus-preserving pancreaticoduodenectomy. World J Surg. 2005 Jul;29(7):881-4. doi: 10.1007/s00268-005-7697-0.
- Busquets J, Martin S, Fabregat J, Secanella L, Pelaez N, Ramos E. Randomized trial of two types of gastrojejunostomy after pancreatoduodenectomy and risk of delayed gastric emptying (PAUDA trial). Br J Surg. 2019 Jan;106(1):46-54. doi: 10.1002/bjs.11023. Epub 2018 Dec 3.
- Tani M, Kawai M, Hirono S, Okada KI, Miyazawa M, Shimizu A, Kitahata Y, Yamaue H. Randomized clinical trial of isolated Roux-en-Y versus conventional reconstruction after pancreaticoduodenectomy. Br J Surg. 2014 Aug;101(9):1084-91. doi: 10.1002/bjs.9544. Epub 2014 Jun 26.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Site
- Endocrine System Diseases
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Endocrine Gland Neoplasms
- Intestinal Diseases
- Intestinal Neoplasms
- Duodenal Diseases
- Biliary Tract Diseases
- Pancreatic Diseases
- Bile Duct Diseases
- Biliary Tract Neoplasms
- Neoplasms
- Pancreatic Neoplasms
- Pancreatitis
- Bile Duct Neoplasms
- Duodenal Neoplasms
Other Study ID Numbers
- WP-0901
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Neoplasms
-
Revolution Medicines, Inc.RecruitingPancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Cancer Metastatic | Pancreatic Adenosquamous Carcinoma | Pancreatic Ductal Adenocarcinoma (PDAC) | PDAC | PDAC - Pancreatic Ductal Adenocarcinoma | Pancreatic Adenocarcinoma MetastaticUnited States
-
Revolution Medicines, Inc.RecruitingPancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Cancer Metastatic | Pancreatic Adenosquamous Carcinoma | Pancreatic Ductal Adenocarcinoma (PDAC) | PDAC | PDAC - Pancreatic Ductal Adenocarcinoma | Pancreatic Adenocarcinoma MetastaticUnited States
-
Revolution Medicines, Inc.AvailablePancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Cancer Metastatic | Pancreatic Adenosquamous Carcinoma | PDAC | PDAC - Pancreatic Ductal Adenocarcinoma | Pancreatic Adenocarcinoma Metastatic | Metastatic Pancreas Adenocarcinoma
-
City of Hope Medical CenterRecruitingPancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Resectable | Pancreatic Carcinoma | Pancreatic Cancer Non-resectable | Pancreatic Cancer Stage III | Pancreatic Cancer Stage | Pancreatic Cancer Stage II | Pancreatic Cancer, Adult | Pancreatic... and other conditionsUnited States, Japan, South Korea
-
Mayo ClinicNational Cancer Institute (NCI)CompletedAdvanced Pancreatic Carcinoma | Metastatic Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Unresectable Pancreatic Carcinoma | Pancreatic Neoplasm | Locally Advanced Pancreatic CarcinomaUnited States
-
Revolution Medicines, Inc.RecruitingPancreatic Cancer | Resected Pancreatic Adenocarcinoma | PDAC | PDAC - Pancreatic Ductal Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma (PDAC)United States, Puerto Rico, United Kingdom
-
Astellas Pharma Global Development, Inc.RecruitingPancreatic Cancer | Metastatic Pancreatic Adenocarcinoma | Metastatic Pancreatic CancerUnited States, Japan
-
PanTher TherapeuticsRecruitingPancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic AdenocarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CelgeneWithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
Clinical Trials on Billroth-II-type reconstruction
-
Sichuan UniversityNot yet recruitingGastric Cancer | Surgery | Gastrostomy | Anastomosis
-
National Healthcare Group, SingaporeChinese University of Hong Kong; Tan Tock Seng Hospital; Changi General HospitalCompletedStomach Cancer | Gastric Cancer | GastrectomySingapore, Hong Kong
-
Jilin UniversityUnknown
-
Fundacion Miguel ServetCompletedPancreatoduodenectomySpain
-
Wakayama Medical UniversityCompleted
-
Korea University Anam HospitalGuangdong Provincial Hospital of Traditional Chinese Medicine; Shanghai Jiao... and other collaboratorsRecruitingDiabetes Mellitus, Type 2 | Gastric CancerKorea, Republic of
-
Shanghai Minimally Invasive Surgery CenterNot yet recruitingPostoperative Complications | Gastric Cancer
-
The First Hospital of Jilin UniversityCompletedGastric Cancer
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityUnknownPostoperative Complications | Nutrition DisordersChina
-
The Catholic University of KoreaWithdrawnStomach Cancer | GastrectomyKorea, Republic of